Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.
By L. Steidler, W. Hans, Lieven Schotte, S. Neirynck, F. Obermeier, W. Falk, W. Fiers, E. Remaut. Science, 2000
1,543 citations recorded by the source corpus.
Subfields: Food Science, Immunology, Nutrition and Dietetics
View Paper: https://www.semanticscholar.org/paper/25c809a9b9303b4cd001a5f83ceebbe45c388fc1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Food Science
In Immunology
In Nutrition and Dietetics
Citations in the corpus
- Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. (2004, background): “[67] Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W,”
- New developments in goblet cell mucus secretion and function (2015, positive): “Interestingly, bacteria manipulated to express IL-10 have been shown to reduce experimental colitis.(78) IL-10 has a direct effect on goblet cells by modulating their ability to manage mucin biosynthesis and misfolding(79) and decreased MUC2 production has been demonstrated in IL-10-deficient mice.”
- Interleukin-10: new perspectives on an old cytokine (2008, background): “Early studies in mice resulted in a 50% decrease in experimental colitis (82), and in Phase I human clinical trials the genetically engineered bacteria were well tolerated in a small group of patients (83).”
- Interleukin-10 Therapy—Review of a New Approach (2003, background): “Steidler et al. (2000) demonstrated that intragastric administration of a genetically engineered IL-10 secreting Lactobacillus lactis caused a significant reduction in colitis in two different mouse models.”
- Structure and evolution of transcriptional regulatory networks. (2004, neutral): “, engineering interactions between bacterial and human cells (Anderson et al. 2006; Steidler et al. 2000); see Chapter 23), bioenergy (e.”
- Probiotics and their fermented food products are beneficial for health (2006, background): “plantarum 299v and DSM 9843 strains were shown in clinical trials to reduce abdominal pain, bloating, flatulence, and constipation (Motta et al. 1991; Steidler et al. 2000; MacFarlane and Cummings 2002).”
- Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease. (2019, background): “…the systemic administration of IL-10 has not been beneficial in IBD (Colombel et al., 2001; Schreiber et al., 2000), the local production of IL-10 in the gut by Lactococcus lactis appears safe (Braat et al., 2006) and ameliorates DSS-induced and IL-10 deficiency colitis (Steidler et al., 2000).”
- Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility (2008, background): “As a delivery mechanism, genetically engineered IL10-secreting Lactococcus lactis strains have been developed as a potent tool to influence colonic mucosal immunoregulatio”